Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)
  4. Fast Track Articles
  5. Fast Track Article
image of Lingguizhugan Decoction in the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
file format pdf download PDF

Abstract

Objective

This study systematically evaluated the efficacy and safety of Ling Gui Zhu Gan Decoction for treating non-alcoholic fatty liver disease.

Methods

Registered under CRD42024501460 on the PROSPERO platform, we searched eight major databases, including Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, Wanfang database, Chinese Scientific Journals Database, and Chinese Biomedicine Database, from inception to December 2023 for randomized controlled trials on Ling Gui Zhu Gan Decoction in non-alcoholic fatty liver disease treatment. We extracted data on total efficiency, TC, TG, ALT, AST, GGT, and HOMA-IR, analyzing results with RevMan 5.4 software.

Results

Twelve studies met the inclusion criteria, encompassing 970 cases. Ling Gui Zhu Gan Decoction, alone or combined with standard therapy, significantly improved non-alcoholic fatty liver disease outcomes, regardless of treatment duration. Only one study reported adverse events, including bloating, diarrhea, nausea, vomiting, and rash.

Conclusion

Ling Gui Zhu Gan Decoction appears to be an effective and safe option for non-alcoholic fatty liver disease treatment. However, due to limited studies and methodological weakness, further rigorous randomized controlled trials are necessary for conclusive results.

© 2025 The Author (s). Published by Bentham Science Publishers
© 2025 The Author (s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303323071241022053842
2025-01-09
2025-05-04

  • From This Site

    /content/journals/emiddt/10.2174/0118715303323071241022053842
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. Maurice J. Manousou P. Non-alcoholic fatty liver disease. Clin. Med. (Lond.) 2018 18 3 245 250 10.7861/clinmedicine.18‑3‑245 29858436
    [Google Scholar]
  2. Younossi Z.M. Koenig A.B. Abdelatif D. Fazel Y. Henry L. Wymer M. Global epidemiology of nonalcoholic fatty liver disease — Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016 64 1 73 84 10.1002/hep.28431 26707365
    [Google Scholar]
  3. Sinn D.H. Kang D. Chang Y. Ryu S. Gu S. Kim H. Seong D. Cho S.J. Yi B.K. Park H.D. Paik S.W. Song Y.B. Lazo M. Lima J.A.C. Guallar E. Cho J. Gwak G.Y. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: A retrospective cohort study. Gut 2017 66 2 323 329 10.1136/gutjnl‑2016‑311854 27599521
    [Google Scholar]
  4. Friedman S.L. Neuschwander-Tetri B.A. Rinella M. Sanyal A.J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 2018 24 7 908 922 10.1038/s41591‑018‑0104‑9 29967350
    [Google Scholar]
  5. Kleiner D.E. Makhlouf H.R. Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. Clin. Liver Dis. 2016 20 2 293 312 10.1016/j.cld.2015.10.011 27063270
    [Google Scholar]
  6. Wree A. Broderick L. Canbay A. Hoffman H.M. Feldstein A.E. From NAFLD to NASH to cirrhosis — New insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 2013 10 11 627 636 10.1038/nrgastro.2013.149 23958599
    [Google Scholar]
  7. Alonso C. Fernández-Ramos D. Varela-Rey M. Martínez-Arranz I. Navasa N. Van Liempd S.M. Lavín Trueba J.L. Mayo R. Ilisso C.P. de Juan V.G. Iruarrizaga-Lejarreta M. delaCruz-Villar L. Mincholé I. Robinson A. Crespo J. Martín-Duce A. Romero-Gómez M. Sann H. Platon J. Van Eyk J. Aspichueta P. Noureddin M. Falcón-Pérez J.M. Anguita J. Aransay A.M. Martínez-Chantar M.L. Lu S.C. Mato J.M. Metabolomic identification of subtypes of nonalcoholic steatohepatitis. Gastroenterology 2017 152 6 1449 1461.e7 10.1053/j.gastro.2017.01.015 28132890
    [Google Scholar]
  8. Luo W. Xu Q. Wang Q. Wu H. Hua J. Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. Sci. Rep. 2017 7 1 44612 10.1038/srep44612 28300213
    [Google Scholar]
  9. Tilg H. Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010 52 5 1836 1846 10.1002/hep.24001 21038418
    [Google Scholar]
  10. Tilg H. Hotamisligil G.S. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006 131 3 934 945 10.1053/j.gastro.2006.05.054 16952562
    [Google Scholar]
  11. Rada P. González-Rodríguez Á. García-Monzón C. Valverde Á.M. Understanding lipotoxicity in NAFLD pathogenesis: Is CD36 a key driver? Cell Death Dis. 2020 11 9 802 10.1038/s41419‑020‑03003‑w 32978374
    [Google Scholar]
  12. Koliaki C. Szendroedi J. Kaul K. Jelenik T. Nowotny P. Jankowiak F. Herder C. Carstensen M. Krausch M. Knoefel W.T. Schlensak M. Roden M. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015 21 5 739 746 10.1016/j.cmet.2015.04.004 25955209
    [Google Scholar]
  13. Neuschwander-Tetri B.A. Non-alcoholic fatty liver disease. BMC Med. 2017 15 1 45 10.1186/s12916‑017‑0806‑8 28241825
    [Google Scholar]
  14. Magkos F. Fraterrigo G. Yoshino J. Luecking C. Kirbach K. Kelly S.C. de las Fuentes L. He S. Okunade A.L. Patterson B.W. Klein S. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016 23 4 591 601 10.1016/j.cmet.2016.02.005 26916363
    [Google Scholar]
  15. Nassir F. NAFLD: Mechanisms, treatments, and biomarkers. Biomolecules 2022 12 6 824 10.3390/biom12060824 35740949
    [Google Scholar]
  16. Sanyal A.J. Chalasani N. Kowdley K.V. McCullough A. Diehl A.M. Bass N.M. Neuschwander-Tetri B.A. Lavine J.E. Tonascia J. Unalp A. Van Natta M. Clark J. Brunt E.M. Kleiner D.E. Hoofnagle J.H. Robuck P.R. NASH CRN Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010 362 18 1675 1685 10.1056/NEJMoa0907929 20427778
    [Google Scholar]
  17. Mahady S.E. Webster A.C. Walker S. Sanyal A. George J. The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis. J. Hepatol. 2011 55 6 1383 1390 10.1016/j.jhep.2011.03.016 21703200
    [Google Scholar]
  18. Friedman S.L. Ratziu V. Harrison S.A. Abdelmalek M.F. Aithal G.P. Caballeria J. Francque S. Farrell G. Kowdley K.V. Craxi A. Simon K. Fischer L. Melchor-Khan L. Vest J. Wiens B.L. Vig P. Seyedkazemi S. Goodman Z. Wong V.W.S. Loomba R. Tacke F. Sanyal A. Lefebvre E. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 2018 67 5 1754 1767 10.1002/hep.29477 28833331
    [Google Scholar]
  19. Sumida Y. Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J. Gastroenterol. 2018 53 3 362 376 10.1007/s00535‑017‑1415‑1 29247356
    [Google Scholar]
  20. Noureddin M. Muthiah M.D. Sanyal A.J. Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. Endocrinol. Diabetes Metab. 2020 3 4 e00105 10.1002/edm2.105 33102791
    [Google Scholar]
  21. Mantovani A. Dalbeni A. Treatments for NAFLD: State of art. Int. J. Mol. Sci. 2021 22 5 2350 10.3390/ijms22052350 33652942
    [Google Scholar]
  22. Rong L. Zou J. Ran W. Qi X. Chen Y. Cui H. Guo J. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front. Endocrinol. (Lausanne) 2023 13 1087260 10.3389/fendo.2022.1087260 36726464
    [Google Scholar]
  23. Tacke F. Puengel T. Loomba R. Friedman S.L. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J. Hepatol. 2023 79 2 552 566 10.1016/j.jhep.2023.03.038 37061196
    [Google Scholar]
  24. Harrison S.A. Bedossa P. Guy C.D. Schattenberg J.M. Loomba R. Taub R. Labriola D. Moussa S.E. Neff G.W. Rinella M.E. Anstee Q.M. Abdelmalek M.F. Younossi Z. Baum S.J. Francque S. Charlton M.R. Newsome P.N. Lanthier N. Schiefke I. Mangia A. Pericàs J.M. Patil R. Sanyal A.J. Noureddin M. Bansal M.B. Alkhouri N. Castera L. Rudraraju M. Ratziu V. MAESTRO-NASH Investigators A phase 3, randomized, controlled trial of resmetirom in nash with liver fibrosis. N. Engl. J. Med. 2024 390 6 497 509 10.1056/NEJMoa2309000 38324483
    [Google Scholar]
  25. Ray K. Resmetirom proves positive for NASH with liver fibrosis. Nat. Rev. Gastroenterol. Hepatol. 2024 21 4 218 10.1038/s41575‑024‑00909‑0 38360990
    [Google Scholar]
  26. Zhou Z. Zhang J. You L. Wang T. Wang K. Wang L. Kong X. Gao Y. Sun X. Application of herbs and active ingredients ameliorate non-alcoholic fatty liver disease under the guidance of traditional Chinese medicine. Front. Endocrinol. (Lausanne) 2022 13 1000727 10.3389/fendo.2022.1000727 36204095
    [Google Scholar]
  27. Zhao C. Ding H. Hu Z. Du Y. Zhou L. Zhou P. Wang L. Pharmacodynamic study and mechanism of action of Lingguizhugan decoction in the intervention of non-alcoholic fatty liver disease. J. Hainan Med. Univ. 1 2024 29 38 10.13210/j.cnki.jhmu.20230927.002
    [Google Scholar]
  28. National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology, Chinese Medical Association & Fatty Liver Expert Committee, Chinese Medical Doctor Association. (2018). Guidelines for the prevention and treatment of nonalcoholic fatty liver disease(2018 updated version). J. Pract. Liver Dis. 2018 21 2 177 186
    [Google Scholar]
  29. Liu N. Yang J. Ma W. Li C. An L. Zhang X. Zou Q. Xiaoyao Powder in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. J. Ethnopharmacol. 2022 288 114999 10.1016/j.jep.2022.114999 35051605
    [Google Scholar]
  30. Wen H. Liang Y. Deng X. Clinical study of Ling Gui Zhu Gan Decoction combined with polyene phosphatidylcholine in the treatment of nonalcoholic fatty liver disease. Henan Traditional Chinese Medicine 2022 42 11 1639 1643 10.16367/j.issn.1003‑5028.2022.11.0347
    [Google Scholar]
  31. Luo H. He W. Li D. Li W. Zhao Q. Effects of Ling Gui Zhu Gan Decoction on oxidative stress level and lipid metabolism in patients with non-alcoholic fatty liver disease with spleen deficiency and phlegm stasis. World J. Integr. Med 2022 17 4 792 795 10.13935/j.cnki.sjzx.220429
    [Google Scholar]
  32. Dong L. Cao X. Cheng L. Xue H. Guo X. Yang Y. Observation on the efficacy of Ling Gui Zhu Gan Decoction combined with polyene phosphatidylcholine in the treatment of nonalcoholic fatty liver disease. Hainan Med 2022 33 1 36 38
    [Google Scholar]
  33. Chen X-H. A randomized controlled study on the improvement of non-alcoholic fatty liver disease by adding Ling Gui Zhu Gan Decoction combined with calorie restriction. Thesis Guangzhou University of Traditional Chinese Medicine 2021
    [Google Scholar]
  34. Shen J. Liang M. Hu Z. Jiang S. Observation on the efficacy of Ling Gui Zhu Gan Decoction combined with Silymarin Capsules in the treatment of nonalcoholic fatty liver disease. Inner Mongol. Tradit. Chin. Med. 2020 39 9 58 59 10.16040/j.cnki.cn15‑1101.2020.09.036
    [Google Scholar]
  35. Xue X. Xie C. Clinical effect and mechanism of action of Yin Chen Ling Gui Zhu Gan Decoction in the treatment of nonalcoholic steatohepatitis. Chin. Med. 2020 15 6 907 911
    [Google Scholar]
  36. Jing X. Study on the effect of Ling Gui Zhu Gan Decoction in intervening non-alcoholic fatty liver disease with spleen yang deficiency formula. Thesis, Shanghai University of Traditional Chinese Medicine 2020
    [Google Scholar]
  37. Yu X. Wang W. Jin J. Pan J. Zhang H. Xing L. Ling Gui Zhu Gan Decoction combined with probiotics for the treatment of nonalcoholic fatty liver disease. J. Changchun Univ. Tradit. Chin. Med. 2019 35 5 891 894 10.13463/j.cnki.cczyy.2019.05.022
    [Google Scholar]
  38. Sun S. Wang Y. Clinical efficacy of self-prepared Ling Gui Zhu Gan Decoction plus reduction combined with western medicine drugs in the treatment of non-alcoholic fatty liver disease. PharmacoEconomics Chin. Med. 2019 14 9 65 68
    [Google Scholar]
  39. Song Q. Li H. Intervention study on serum NO level in patients with nonalcoholic fatty liver disease by adding Ling Gui Zhu Gan Decoction. Inner Mongol. Tradit. Chin. Med. 2014 33 10 3 4 10.16040/j.cnki.cn15‑1101.2014.10.019
    [Google Scholar]
  40. Song Q. Li H. Clinical study on the treatment of nonalcoholic fatty liver disease by adding Ling Gui Zhu Gan Decoction. Sichuan Tradit. Chin. Med. 2013 31 08 60 62
    [Google Scholar]
  41. Li J. Clinical study on the treatment of non-alcoholic fatty liver disease (phlegm and stasis mutual conjugation syndrome) by adding flavor Ling Gui Zhu Gan granules. Thesis, Guangxi University of Chinese Medicine 2011
    [Google Scholar]
  42. Zhang Y. Effects of poria cocos complex extract on blood glucose and lipid levels in type 2 diabetic rats. Jilin Daxue Xuebao. Yixue Ban 2020 46 05 937 941
    [Google Scholar]
  43. Cao L. Xu E. Zheng R. Zhangchen Z. Zhong R. Huang F. Ye J. Sun H. Fan Y. Xie S. Chen Y. Xu Y. Cao J. Cao W. Liu C. Traditional Chinese medicine Lingguizhugan decoction ameliorate HFD-induced hepatic-lipid deposition in mice by inhibiting STING-mediated inflammation in macrophages. Chin. Med. 2022 17 1 7 10.1186/s13020‑021‑00559‑3 34983596
    [Google Scholar]
  44. Dang Y. Hao S. Zhou W. Zhang L. Ji G. The traditional Chinese formulae Ling-gui-zhu-gan decoction alleviated non-alcoholic fatty liver disease via inhibiting PPP1R3C mediated molecules. BMC Complement. Altern. Med. 2019 19 1 8 10.1186/s12906‑018‑2424‑1 30616587
    [Google Scholar]
  45. Huang J. Du Y. Yan J. Hu Y. Li X. Effects of adding Ling Gui Zhu Gan Decoction on serum resistin, lipocalin, insulin, and insulin resistance in rats with metabolic syndrome. Chin. J. Exp. Formulas 2013 19 06 227 230 10.13422/j.cnki.syfjx.2013.06.079
    [Google Scholar]
  46. Cao L. Molecular mechanism study of Ling Gui Zhu Gan decoction in treating non-alcoholic fatty liver disease by inhibiting STING-mediated signaling pathway. Thesis, Nanjing University of Traditional Chinese Medicine 2022
    [Google Scholar]
  47. Bu L. Experimental study on the effect of TNF-α and Leptin on cytokines in NAFLD rats by adding flavor Ling Gui Zhu Gan Decoction based on turbid and stasis treatment. Thesis, Shanxi University of Traditional Chinese Medicine 2018
    [Google Scholar]
/content/journals/emiddt/10.2174/0118715303323071241022053842
Loading
Lingguizhugan Decoction in the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Bentham Science Publishers ; https://doi.org/10.2174/0118715303323071241022053842
/content/journals/emiddt/10.2174/0118715303323071241022053842
/content/journals/emiddt/10.2174/0118715303323071241022053842
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: Ling Gui Zhu Gan Decoction ; controlled trials ; non-alcoholic fatty liver disease ; traditional Chinese medicine ; systematic review ; meta-analysis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test